• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?

作者信息

Gouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose

机构信息

Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.

出版信息

J Thorac Oncol. 2014 Mar;9(3):e27-8. doi: 10.1097/JTO.0000000000000113.

DOI:10.1097/JTO.0000000000000113
PMID:24518097
Abstract
摘要

相似文献

1
Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?克唑替尼可克服对CH5424802的获得性耐药：MET基因扩增是关键因素吗？
J Thorac Oncol. 2014 Mar;9(3):e27-8. doi: 10.1097/JTO.0000000000000113.
2
Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.一名ALK阳性腺癌合并弥散性血管内凝血患者对克唑替尼产生显著反应。
J Thorac Oncol. 2013 Nov;8(11):e96-8. doi: 10.1097/JTO.0b013e3182a008ed.
3
Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c- MET amplification.一名患有携带c-MET扩增的肺腺癌患者对克唑替尼完全缓解。
J BUON. 2017 Jan-Feb;22(1):279-280.
4
Crizotinib in the management of advanced-stage non-small-cell lung cancer.克唑替尼用于晚期非小细胞肺癌的治疗
Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314.
5
Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.通过下一代测序进行循环肿瘤DNA分析揭示了一名MET扩增的胃癌患者中克唑替尼耐药机制的异质性。
Oncotarget. 2017 Apr 18;8(16):26281-26287. doi: 10.18632/oncotarget.15457.
6
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.对吉非替尼耐药但对克唑替尼敏感的肺腺癌患者，同时存在表皮生长因子受体罕见突变（L861Q）以及ALK/MET/ROS1基因拷贝数增加。
J Thorac Oncol. 2013 Dec;8(12):e105-6. doi: 10.1097/JTO.0b013e3182a00e37.
7
[Interest of crizotinib in a lung cancer patient with de novo amplification of MET].克唑替尼对一名MET基因发生新发扩增的肺癌患者的疗效
Rev Mal Respir. 2017 Jan;34(1):57-60. doi: 10.1016/j.rmr.2016.05.007. Epub 2016 Oct 13.
8
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.在 ALK 阳性非小细胞肺癌患者中，在用选择性 ALK 抑制剂阿来替尼治疗后，激活的 MET 充当挽救信号。
Int J Oncol. 2015 Mar;46(3):1025-30. doi: 10.3892/ijo.2014.2797. Epub 2014 Dec 15.
9
High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.高剂量克唑替尼用于治疗对标准剂量克唑替尼难治的脑转移瘤。
J Thorac Oncol. 2013 Sep;8(9):e85-6. doi: 10.1097/JTO.0b013e31829cebbb.
10
Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.非小细胞肺癌中MET外显子14跳跃导致克唑替尼耐药的获得性机制
J Thorac Oncol. 2019 Jul;14(7):e137-e139. doi: 10.1016/j.jtho.2019.04.021. Epub 2019 May 2.

引用本文的文献

1
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.非小细胞肺癌中靶向治疗和免疫治疗的耐药机制：克服挑战的有前景策略
Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.
2
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?ALK 易位阳性非小细胞肺癌（NSCLC）患者管理的持续改善：我们进展如何？
Curr Oncol. 2023 May 16;30(5):5072-5092. doi: 10.3390/curroncol30050384.
3
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review.
克服非小细胞肺癌中对ALK抑制剂耐药的策略：一项叙述性综述
Transl Lung Cancer Res. 2023 Mar 31;12(3):615-628. doi: 10.21037/tlcr-22-708. Epub 2023 Mar 20.
4
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.Tepotinib 联合吉非替尼对比化疗用于因 MET 扩增导致 EGFR 抑制剂耐药的 EGFR 突变 NSCLC 的随机试验：INSIGHT 最终分析。
Clin Cancer Res. 2023 May 15;29(10):1879-1886. doi: 10.1158/1078-0432.CCR-22-3318.
5
Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene.克唑替尼治疗棘皮动物微管相关蛋白样 4-间变性淋巴瘤激酶融合基因肺癌患者耐药获得成功，可能与间充质上皮转化扩增有关。
Intern Med. 2023 Nov 1;62(21):3215-3221. doi: 10.2169/internalmedicine.1164-22. Epub 2023 Mar 15.
6
Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis.ALK 抑制剂治疗初治 ALK 阳性晚期伴中枢神经系统转移的非小细胞肺癌的疗效比较：一项网络荟萃分析。
Int J Mol Sci. 2023 Jan 23;24(3):2242. doi: 10.3390/ijms24032242.
7
MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities.MET扩增作为肺癌中TKI治疗的耐药驱动因素：临床挑战与机遇
Cancers (Basel). 2023 Jan 18;15(3):612. doi: 10.3390/cancers15030612.
8
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.非小细胞肺癌中的分子通路、耐药机制及靶向干预
Mol Biomed. 2022 Dec 12;3(1):42. doi: 10.1186/s43556-022-00107-x.
9
The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2/3-Generation ALK Tyrosine Kinase Inhibitors (TKIs).二代/三代间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKIs）治疗失败后，综合基因组分析（CGP）对ALK重排的晚期非小细胞肺癌（aNSCLC）治疗决策过程的影响
Front Oncol. 2022 May 13;12:874712. doi: 10.3389/fonc.2022.874712. eCollection 2022.
10
Complex genetic alterations contribute to rapid disease progression in an rearrangement lung adenocarcinoma patient: a case report.复杂基因改变导致一例重排型肺腺癌患者疾病快速进展：病例报告
Transl Cancer Res. 2021 Jun;10(6):3081-3086. doi: 10.21037/tcr-20-3473.